|
|
 Previous Article | Table of Contents | Next Article 
Blood, 1 December 2000, Vol. 96, No. 12, pp. 3847-3856
IMMUNOBIOLOGY
Up-regulation of costimulatory/adhesion molecules by histone
deacetylase inhibitors in acute myeloid leukemia cells
Takahiro Maeda,
Masayuki Towatari,
Hiroshi Kosugi, and
Hidehiko Saito
From the First Department of Internal Medicine, Nagoya
University School of Medicine, Nagoya, Japan.
Histone deacetylase inhibitors (HDACIs) have been used to focus on
the effects of inducing gene expression through the acetylation of
histones which results in chromatin remodeling. The
study explored whether HDACIs could induce the expression of
costimulatory/adhesion molecules on acute myeloid leukemia (AML) cells,
thereby effectively inducing tumor immunity. The expression of CD80,
CD86, human leukocyte antigen (HLA)-DR, HLA-ABC, and intracellular
adhesion molecule-1 (ICAM-1) was tested in human AML cell lines after
the addition of HDACI, sodium butyrate (SB). Generally, increased
expression of CD86 was observed by SB treatment in a majority of cell
lines, and ICAM-1 was expressed in fewer cell lines. Essentially the same results were obtained using other HDACIs such as FR901228, trichostatin A, and trapoxin A. Quantitation of transcripts of CD86 accompanied with RNA synthesis inhibition assay and nuclear run-on
assay revealed that SB up-regulates the CD86 expression transcriptionally. Furthermore, chromatin immunoprecipitation experiments showed that HDACI treatment caused remarkable acetylation on histone H3 and H4 at CD86 promoter chromatin in vivo. In 30 clinical
AML samples, CD86 expression was significantly increased (P < .001) by SB treatment, and the expression of HLA-DR
and ICAM-1 was moderately increased (P < .05) by SB
treatment. Finally, the allogeneic mixed leukocyte reaction (allo-MLR)
against HL60 cells pretreated with SB was enhanced 4-fold compared with
allo-MLR obtained with non-treated HL60 cells. These results
suggest that the immunotherapeutic use of HDACIs may become a novel
tool for treatment of AML.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S.-N. Kim, N. H. Kim, W. Lee, D.-W. Seo, and Y. K. Kim
Histone Deacetylase Inhibitor Induction of P-Glycoprotein Transcription Requires Both Histone Deacetylase 1 Dissociation and Recruitment of CAAT/Enhancer Binding Protein {beta} and pCAF to the Promoter Region
Mol. Cancer Res.,
May 1, 2009;
7(5):
735 - 744.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Imai, K. Ochiai, and T. Okamoto
Reactivation of Latent HIV-1 Infection by the Periodontopathic Bacterium Porphyromonas gingivalis Involves Histone Modification
J. Immunol.,
March 15, 2009;
182(6):
3688 - 3695.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Schmidt, K. Seeger, C. Scheibenbogen, R. Bender, M. Abdulla, S. Sussmilch, A. Salama, and A. Moldenhauer
Histone deacetylase inhibition improves differentiation of dendritic cells from leukemic blasts of patients with TEL/AML1-positive acute lymphoblastic leukemia
J. Leukoc. Biol.,
March 1, 2009;
85(3):
563 - 573.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. M. Klimek, S. Fircanis, P. Maslak, I. Guernah, M. Baum, N. Wu, K. Panageas, J. J. Wright, P. P. Pandolfi, and S. D. Nimer
Tolerability, Pharmacodynamics, and Pharmacokinetics Studies of Depsipeptide (Romidepsin) in Patients with Acute Myelogenous Leukemia or Advanced Myelodysplastic Syndromes
Clin. Cancer Res.,
February 1, 2008;
14(3):
826 - 832.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Ishihama, M. Yamakawa, S. Semba, H. Takeda, S. Kawata, S. Kimura, and W. Kimura
Expression of HDAC1 and CBP/p300 in human colorectal carcinomas
J. Clin. Pathol.,
November 1, 2007;
60(11):
1205 - 1210.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Kato, K. Yoshimura, T. Shin, H. Verheul, H. Hammers, T. B. Sanni, B. C. Salumbides, K. Van Erp, R. Schulick, and R. Pili
Synergistic In vivo Antitumor Effect of the Histone Deacetylase Inhibitor MS-275 in Combination with Interleukin 2 in a Murine Model of Renal Cell Carcinoma
Clin. Cancer Res.,
August 1, 2007;
13(15):
4538 - 4546.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M.E.I. Hellebrekers, K. Castermans, E. Vire, R. P.M. Dings, N. T.H. Hoebers, K. H. Mayo, M. G.A. oude Egbrink, G. Molema, F. Fuks, M. van Engeland, et al.
Epigenetic Regulation of Tumor Endothelial Cell Anergy: Silencing of Intercellular Adhesion Molecule-1 by Histone Modifications.
Cancer Res.,
November 15, 2006;
66(22):
10770 - 10777.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Achachi, A. Florins, N. Gillet, C. Debacq, P. Urbain, G. M. Foutsop, F. Vandermeers, A. Jasik, M. Reichert, P. Kerkhofs, et al.
Valproate activates bovine leukemia virus gene expression, triggers apoptosis, and induces leukemia/lymphoma regression in vivo
PNAS,
July 19, 2005;
102(29):
10309 - 10314.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Armeanu, M. Bitzer, U. M. Lauer, S. Venturelli, A. Pathil, M. Krusch, S. Kaiser, J. Jobst, I. Smirnow, A. Wagner, et al.
Natural Killer Cell-Mediated Lysis of Hepatoma Cells via Specific Induction of NKG2D Ligands by the Histone Deacetylase Inhibitor Sodium Valproate
Cancer Res.,
July 15, 2005;
65(14):
6321 - 6329.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Byrd, G. Marcucci, M. R. Parthun, J. J. Xiao, R. B. Klisovic, M. Moran, T. S. Lin, S. Liu, A. R. Sklenar, M. E. Davis, et al.
A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia
Blood,
February 1, 2005;
105(3):
959 - 967.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Moldenhauer, R. C. Frank, J. Pinilla-Ibarz, G. Holland, P. Boccuni, D. A. Scheinberg, A. Salama, K. Seeger, M. A. S. Moore, and S. D. Nimer
Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins
J. Leukoc. Biol.,
September 1, 2004;
76(3):
623 - 633.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A Buda, D Qualtrough, M A Jepson, D Martines, C Paraskeva, and M Pignatelli
Butyrate downregulates {alpha}2{beta}1 integrin: a possible role in the induction of apoptosis in colorectal cancer cell lines
Gut,
May 1, 2003;
52(5):
729 - 734.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
A. P. Kohm, A. Mozaffarian, and V. M. Sanders
B Cell Receptor- and {beta}2-Adrenergic Receptor-Induced Regulation of B7-2 (CD86) Expression in B Cells
J. Immunol.,
June 15, 2002;
168(12):
6314 - 6322.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. N. Laribee and M. J. Klemsz
Loss of PU.1 Expression Following Inhibition of Histone Deacetylases
J. Immunol.,
November 1, 2001;
167(9):
5160 - 5166.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
